Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Genomic and chromosomal instability are hallmarks of cancer and shape the genomic
composition of cancer cells, thereby determining their behavior and response to treatment …

Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional
defects in this pathway through synthetic lethal mechanisms. For example, defects in …

Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple
components of the DNA damage response (DDR) operate as bona fide tumor suppressor …

The discovery of cancer immune surveillance and immunotherapy has opened up a new era
of cancer treatment. Immunotherapies modulate a patient's immune system to specifically …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …

Sister chromatid exchanges (SCEs) are products of joint DNA molecule resolution, and are
considered to form through homologous recombination (HR). Indeed, SCE induction upon …